# A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

> **NCT06487572** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 60 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT06487572
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-23
- **Primary completion:** 2025-02-07
- **Final completion:** 2025-02-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487572, "A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06487572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*